New eye imaging could reveal hidden clues to vision loss

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (from the main study): * 50 years or older and may be either male or female and may be of any race * Established diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD) * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude participants from participation * Willing to participate as evidenced by signing the written informed consent Additional Sub-study Inclusion Criteria: * Early-stage GA defined as * GA area of between 1.25 mm2 and 23 mm2 * GA may be unifocal or multifocal * GA may be subfoveal or extrafoveal * Concurrent peripapillary atrophy will not exclude participant from participation * Phakic and pseudophakic participants are eligible for enrollment, with phakic participants prioritized when feasible. Exclusion Criteria (from the main study): * Unable to tolerate ophthalmic imaging * Presence of neovascular AMD on optical coherence tomography (OCT) as confirmed by an ophthalmologist * Presence of significant media opacity preventing adequate retinal imaging * Presence of concurrent retinal disease which may confound assessment Additional Sub-study Exclusion Criteria: * Ocular media opacity or other condition(s) that, in the opinion of the investigators, may preclude imaging. * Individuals who, in the opinion of the investigator, are unable to tolerate study procedures or comply with study requirements. * Prior or current treatment with intraocular injections for geographic atrophy (e.g., pegcetacoplan \[Syfovre\] or similar therapies) is not permitted.